Leukemia research最新文献

{"title":"Molecular characterization of V(D)J rearrangements in immature acute leukemias","authors":"","doi":"10.1016/j.leukres.2024.107521","DOIUrl":"10.1016/j.leukres.2024.107521","url":null,"abstract":"<div><p><span>Early T-cell Precursor Acute Lymphoblastic Leukemia<span> (ETP-ALL), T-Lymphoid/Myeloid Mixed Phenotype Acute Leukemia<span> (T/M-MPAL), and Acute Myeloid Leukemia<span> with minimal differentiation (AML-M0) are immature acute leukemias (AL) that present overlapping T-cell lymphoid and myeloid features at different degrees, with impact to disease classification. An interesting strategy to assess lymphoid lineage commitment and maturation is the analysis of V(D)J gene segment recombination, which can be applied to investigate leukemic cells in immature AL. Herein, we revisited 19 ETP-ALL, 8 T/M-MPAL, and 12 AML-M0 pediatric patients to characterize V(D)J rearrangement (V(D)J-r) profiles associated with other somatic alterations. V(D)J-r were identified in 74 %, 25 %, and 25 % of ETP-ALL, T/M-MPAL, and AML-M0, respectively. Forty-six percent of ETP-ALL harbored ≥ 3 V(D)J-r, while there was no more than one V(D)J-r per patient in AML-M0 and T/M-MPAL. TCRD was the most rearranged locus in ETPALL, but it was not rearranged in other AL. In ETP-ALL, N/KRAS mutations were associated with </span></span></span></span>absence<span> of V(D)J-r, while NF1 deletion was most frequent in patients with ≥ 3 V(D)J-r. Relapse and death occurred mainly in patients harboring one or no rearranged locus. Molecular characterization of V(D)J-r in our cohort indicates a distinct profile of ETP-ALL, compared to T/M-MPAL and AML-M0. Our findings also suggest that the clinical outcome of ETP-ALL patients may be affected by blast cell maturity, inferred from the number of rearranged TCR loci.</span></p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"143 ","pages":"Article 107521"},"PeriodicalIF":2.1,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141275662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arsenic trioxide regulates the glycolytic pathway to treat acute promyelocytic leukemia by inhibiting RPL22L1","authors":"Heran Cui ,&nbsp;Yuanyang Ma ,&nbsp;Shulin Han ,&nbsp;Xiaodong Zhang ,&nbsp;Weiya Fu ,&nbsp;Shuang Yang ,&nbsp;Tianhang Liu ,&nbsp;Xuefang Zhang","doi":"10.1016/j.leukres.2024.107550","DOIUrl":"10.1016/j.leukres.2024.107550","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the relationship between the treatment of acute promyelocytic leukemia (APL) with arsenic trioxide (ATO) and glycolysis, as well as its underlying molecular mechanism.</p></div><div><h3>Methods</h3><p>The GEO database was used to analyze alterations in the expression of RPL22L1 in APL patients and its correlation with glycolysis. The levels of RPL22L1 and glycolysis were assessed in 9 paired clinical samples. NB4 cells and NB4 cells with knockdown of RPL22L1 were treated with ATO. The protein and mRNA of RPL22L1 were detected using RT-PCR and Western blot, and the content was determined by using glucose, pyruvate, and lactate detection kits. Finally, detection of cell proliferation using CCK8, migration by scratch assay, and apoptosis by flow cytometry, and the biological function of ATO in NB4 cells was examined.</p></div><div><h3>Results</h3><p>The expression of RPL22L1 in GSE213742 and GSE234103 datasets exhibited a significant increase in human APL cells, specifically NB4 cells. RPL22L1 in GSE213742 and GSE234103 gene expression matrix was significantly elevated in human APL cells NB4 cells, and further analysis found RPL22L1 showed a strong positive correlation with glycolysis. Cellular experiments showed that ATO inhibited RPL22L1 in NB4 cells and inhibited glycolysis in APL cells. The ATO played a pivotal role in suppressing the proliferation, migration, as well as invasion of NH4 cells.</p></div><div><h3>Conclusion</h3><p>ATO regulates the blycolytic pathway in APL by inhibiting RPL22L1 expression, and this may contribute to its therapeutic effects.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"144 ","pages":"Article 107550"},"PeriodicalIF":2.1,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141845598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis","authors":"Matteo Molica ,&nbsp;Salvatore Perrone ,&nbsp;Marco Rossi,&nbsp;Diana Giannarelli","doi":"10.1016/j.leukres.2024.107549","DOIUrl":"10.1016/j.leukres.2024.107549","url":null,"abstract":"<div><p>FLT3 inhibitors combined with chemotherapy are the standard of care for newly diagnosed FLT3-mutated acute myeloid leukemia (AML). However, no head-to-head studies have established the superiority of one FLT3 inhibitor over another. We conducted a network meta-analysis (NMA) to evaluate overall survival (OS) among different FLT3 inhibitors. Three relevant randomized controlled trials (RCTs), involving 1.358 patients treated with midostaurin, quizartinib, and sorafenib, were included in our analysis. The hazard ratios (HRs) revealed no significant differences in OS between midostaurin and quizartinib (HR, 1.00; 95 % CI, 0.73–1.36), midostaurin and sorafenib (HR, 0.97; 95 % CI, 0.52–1.84), or quizartinib and sorafenib (HR, 0.97; 95 % CI, 0.51–1.85). This NMA, the first to explore this issue, found no OS differences among the different FLT3 inhibitors. In the absence of direct comparison trials, our findings provide practical insights for clinical decision-making.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"144 ","pages":"Article 107549"},"PeriodicalIF":2.1,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141788541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia","authors":"Chunfang Kong ,&nbsp;Mei Wu ,&nbsp;Qilin Lu ,&nbsp;Bo Ke ,&nbsp;Jianhui Xie ,&nbsp;Anna Li","doi":"10.1016/j.leukres.2024.107548","DOIUrl":"10.1016/j.leukres.2024.107548","url":null,"abstract":"<div><h3>Purpose</h3><p>Pirtobrutinib, a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, has been approved as the first agent to overcome resistance to covalent BTK inhibitors (such as ibrutinib, acalabrutinib, and zanubrutinib). However, the mechanisms of pirtobrutinib resistance in chronic lymphocytic leukemia (CLL) remain poorly understood.</p></div><div><h3>Methods</h3><p>To investigate pirtobrutinib resistance, we established resistant cell models using BTK knock-out via CRISPR-Cas9 or chronic exposure to pirtobrutinib in MEC-1 cells. These models mimicked intrinsic or acquired resistance, respectively. We then analyzed differential protein expression between wild-type (WT) and resistant MEC-1 cells using Revers Phase Protein microArray (RPPA) and confirmed the findings through Western Blot. Additionally, we evaluated potential drugs to overcome pirtobrutinib resistance by conducting cell proliferation assays, apoptosis studies, and animal experiments using both sensitive and resistant cells.</p></div><div><h3>Results</h3><p>MEC-1 cells developed resistance to pirtobrutinib either through BTK knock-out or prolonged drug exposure over three months. RPPA analysis revealed significant activation of proteins related to the PI3K/AKT pathway, including AKT and S6, in the resistant cells. Western Blot confirmed increased phosphorylation of AKT and S6 in pirtobrutinib-resistant MEC-1 cells. Notably, both the PI3K inhibitor (CAL101) and the AKT inhibitor (MK2206) effectively reduced cell proliferation and induced apoptosis in the resistant cells. The anti-tumor efficacy of these drugs was mediated by inhibiting the PI3K/AKT pathway. In vivo animal studies further supported the potential of targeting PI3K/AKT to overcome both intrinsic and acquired resistance to pirtobrutinib.</p></div><div><h3>Conclusion</h3><p>The PI3K/AKT pathway plays a crucial role in both intrinsic and acquired resistance to pirtobrutinib in CLL. Therapeutically targeting this pathway may offer a promising strategy to overcome pirtobrutinib resistance.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"144 ","pages":"Article 107548"},"PeriodicalIF":2.1,"publicationDate":"2024-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0145212624001140/pdfft?md5=0b6090d405f87272f93ede9712591792&pid=1-s2.0-S0145212624001140-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141623408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia","authors":"Kanak Parmar ,&nbsp;Rupayan Kundu ,&nbsp;Abhishek Maiti ,&nbsp;Somedeb Ball","doi":"10.1016/j.leukres.2024.107546","DOIUrl":"10.1016/j.leukres.2024.107546","url":null,"abstract":"<div><p>Acute myeloid leukemia with antecedent hematologic disorder (AHD-AML) and therapy related AML (t-AML) constitute a heterogenous disease with inferior outcomes. It is often characterized by high-risk cytogenetic and molecular alterations associated with AHD or prior cancer therapy. Historically, the standard of care treatment has been intensive induction with “7 + 3”, with an improved overall response rate and survival with CPX-351. Results from large registry-based studies suggested that allogeneic hematopoietic stem cell transplant is preferable to consolidation chemotherapy alone for achieving long-term survival in patients with AHD-AML. Prevalence of high-risk genetic features and advanced age and comorbidities in patients make AHD-AML and t-AML clinically challenging subgroups to treat with intensive approaches. Recent reports on less intensive treatment options, particularly the hypomethylating agent-venetoclax combination, have shown encouraging response rates in these patients. However, emerging resistance mechanisms compromise duration of response and overall survival. Several novel agents targeting apoptotic machinery, signaling pathways, and immune checkpoints are under clinical investigation, with an aim to truly improve overall outcomes in this subgroup. We reviewed updates in biology, classification, and clinical data comparing safety and efficacy of intensive and less intensive treatment options, and summarized ongoing studies with promising novel therapies in AHD-AML and t-AML.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"144 ","pages":"Article 107546"},"PeriodicalIF":2.1,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141568541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple myeloma and infections in the era of novel treatment modalities","authors":"Mobil Akhmedov ,&nbsp;Pervin Zeynalova ,&nbsp;Alexander Fedenko","doi":"10.1016/j.leukres.2024.107544","DOIUrl":"10.1016/j.leukres.2024.107544","url":null,"abstract":"<div><p>Infections are major cause of morbidity and mortality in patients with multiple myeloma. Current treatment landscape of newly-diagnosed multiple myeloma includes different classes of drugs, such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, all of which are characterized by specific risk and pattern of infectious complications. Additionally, autologous and allogeneic hematopoietic cell transplantation, widely used in the treatment of multiple myeloma, are complex procedures, carrying a significant risk of complications, and mainly infections. Finally, novel treatment modalities such as bispecific T-cell engagers and chimeric antigen receptor T-lymphocytes have been changing the paradigm of myeloma treatment in relapsed-refractory setting. These agents due to unique mechanism of action carry distinct pattern of infectious complications. In this review, an attempt has been made to summarize the incidence, risk factors, and patterns of infections during different stages of myeloma treatment including novel treatment modalities, and to provide evidence underlying the current concept of infectious disease prophylaxis in this category of patients.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"143 ","pages":"Article 107544"},"PeriodicalIF":2.1,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141534758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML","authors":"Shuangshuang Wu ,&nbsp;Fangbing Liu ,&nbsp;Yuqing Gai ,&nbsp;Jenna Carter ,&nbsp;Holly Edwards ,&nbsp;Maik Hüttemann ,&nbsp;Guan Wang ,&nbsp;Chunhuai Li ,&nbsp;Jeffrey W. Taub ,&nbsp;Yue Wang ,&nbsp;Yubin Ge","doi":"10.1016/j.leukres.2024.107547","DOIUrl":"10.1016/j.leukres.2024.107547","url":null,"abstract":"<div><p><em>FMS-like tyrosine kinase 3</em> (<em>FLT3</em>) mutations occur in approximately one third of acute myeloid leukemia (AML) patients. <em>FLT3</em>-Internal tandem duplication (<em>FLT3</em>-ITD) mutations are the most common <em>FLT3</em> mutations and are associated with a poor prognosis. Gilteritinib is a FLT3 inhibitor that is US FDA approved for treating adult patients with relapsed/refractory AML and a <em>FLT3</em> mutation. While gilteritinib monotherapy has improved patient outcome, few patients achieve durable responses. Combining gilteritinib with venetoclax (VEN) appears to make further improvements, though early results suggest that patients with prior exposure to VEN fair much worse than those without prior exposure. MRX-2843 is a promising inhibitor of FLT3 and MERTK. We recently demonstrated that MRX-2843 is equally potent as gilteritinib in <em>FLT3</em>-ITD AML cell lines <em>in vitro</em> and primary patient samples <em>ex vivo</em>. In this study, we investigated the combination of VEN and MRX-2843 against <em>FLT3</em>-ITD AML cells. We found that VEN synergistically enhances cell death induced by MRX-2843 in <em>FLT3</em>-mutated AML cell lines and primary patient samples. Importantly, we found that VEN synergistically enhances cell death induced by MRX-2843 in <em>FLT3</em>-ITD AML cells with acquired resistance to cytarabine (AraC) or VEN+AraC. VEN and MRX-2843 significantly reduce colony-forming capacity of <em>FLT3</em>-ITD primary AML cells. Mechanistic studies show that MRX-2843 decreases Mcl-1 and c-Myc protein levels via transcriptional regulation and combined MRX-2843 and VEN significantly decreases oxidative phosphorylation in <em>FLT3</em>-ITD AML cells. Our findings highlight a promising combination therapy against <em>FLT3</em>-ITD AML, supporting further <em>in vitro</em> and <em>in vivo</em> testing.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"144 ","pages":"Article 107547"},"PeriodicalIF":2.1,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141538008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML","authors":"Stephanie Boisclair ,&nbsp;Edward Zhou ,&nbsp;Phyu Naing ,&nbsp;Richa Thakur ,&nbsp;Erin Jou ,&nbsp;Bradley Goldberg ,&nbsp;Douglas E. Gladstone ,&nbsp;Steven L. Allen ,&nbsp;Jonathan E. Kolitz ,&nbsp;David W. Chitty","doi":"10.1016/j.leukres.2024.107545","DOIUrl":"10.1016/j.leukres.2024.107545","url":null,"abstract":"<div><p>Venetoclax (Ven) combined with a hypomethylating agent (HMA) enhances survival in elderly/unfit acute myeloid leukemia (AML) patients, yet often necessitates regimen modifications due to intolerance. However, it is unclear how these modifications affect patient outcome. This retrospective cohort study evaluates the impact of post-induction HMA/Ven regimen modifications on disease progression and survival. This study reviewed 142 AML patients treated with HMA/Ven within the Northwell Health System from January 2019 to December 2022. To assess the impact of post-induction regimen modifications, patients were grouped according to median days between cycles (≤34 or ≥35 days cycle intervals) and median Ven days per cycle (≤14 or ≥15 days/cycle) based on only cycle 3 and beyond. Kaplan-Meier and Cox proportional hazard regression analyses were employed for univariate and multivariate assessments, respectively. There was no significant difference in median progression-free survival (mPFS)(11.6 vs 11.8 months, p = 0.73) or median overall survival (mOS)(15.1 vs 21.8 months, p = 0.16) between cycle interval groups. However, there was a clinically and statistically significant advantage in mPFS (15.8 vs 8.7 months, p = 0.01) and mOS (24.7 vs 11.3 months, p = 0.006) for patients with a median of ≤14 Ven days/cycle compared to ≥15 Ven days/cycle. Multivariate analysis demonstrated that ≤14 days of Ven for cycle 3 and beyond was an independent predictor of decreased mortality (HR 0.18, CI 0.07–0.48, p = 0.0007). Extended cycle intervals did not adversely affect mortality while reduced Ven duration per cycle post-induction was associated with improved survival in elderly AML patients.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"143 ","pages":"Article 107545"},"PeriodicalIF":2.1,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141526462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-transplant cyclophosphamide: A double-edged sword?","authors":"Alessandro Busca","doi":"10.1016/j.leukres.2024.107543","DOIUrl":"10.1016/j.leukres.2024.107543","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"143 ","pages":"Article 107543"},"PeriodicalIF":2.1,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141450832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of clonal relationship and prognostic significance in acute myeloid leukemia patients with concomitant increase in mast cells","authors":"Zhifang Xu ,&nbsp;Ting Zhang ,&nbsp;Jian Hao ,&nbsp;Dan Liu ,&nbsp;Minglin Hong ,&nbsp;Shaotong Dong ,&nbsp;Ju Deng ,&nbsp;Fanggang Ren ,&nbsp;Yaofang Zhang ,&nbsp;Hongwei Wang","doi":"10.1016/j.leukres.2024.107539","DOIUrl":"10.1016/j.leukres.2024.107539","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"143 ","pages":"Article 107539"},"PeriodicalIF":2.1,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141469206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}